'Cosmic miracle!' James Webb Space Telescope discovers the earliest galaxy ever seen
When you buy through links on our articles, Future and its syndication partners may earn a commission.
The James Webb Space Telescope (JWST) excels at a lot of things, but there are two things it does better than any other scientific instrument in human history: spotting early galaxies and breaking its own records!Now, the $10 billion NASA space telescope has done both things again, detecting a galaxy that existed just 280 million years after the Big Bang, a feat that the team behind this research has dubbed a "cosmic miracle."Currently, as the earliest and most distant galaxy ever detected, this "the mother of all early galaxies," this new JWST discovery has been fittingly designated "MoM z14."
"First and foremost, at the moment, this is the most distant object known to humanity. That title changes every so often, but I find it is always cause for pause and reflection," team member and Yale University professor of Astronomy and Physics Pieter van Dokkum told Space.com. "MoM z14 existed when the universe was about 280 million years old - we're getting quite close to the Big Bang.
"Just to put that in context, sharks have been around on Earth for a longer timespan!"
Since it began sending data back to Earth in the summer of 2022, the JWST has excelled in detecting galaxies at so-called "high redshifts." Redshift refers to the phenomenon of the wavelength of light from distant and thus early sources being stretched and shifted toward the "red end" of the electromagnetic spectrum as it traverses expanding space. The earlier and thus further away an object is, the greater the redshift.
Prior to the discovery of MoM z14, the galaxy holding the title of earliest and distant was JADES-GS-z14-0, which existed just 300 million years after the Big Bang, or around 13.5 billion years ago. This previous record galaxy has a redshift of z =14.32, while MoM z14 has a redshift of z = 14.44.
There is a wider context to the observation of MoM z14 than the fact that it has broken the record for earliest known galaxy by 20 million years, though, as van Dokkum explained.
"The broader story here is that JWST was not expected to find any galaxies this early in the history of the universe, at least not at this stage of the mission," van Dokkum said. "There are, very roughly, over 100 more relatively bright galaxies in the very early universe than were expected based on pre-JWST observations."Also, in addition to detecting this new, earliest, and most distant galaxy, the team was able to determine some of its characteristics using the JWST.
The researchers were able to determine that MoM z14 is around 50 times smaller than the Milky Way. The team also measured emission lines from the galaxy, indicating the presence of elements like nitrogen and carbon.
"The emission lines are unusual; it indicates that the galaxy is very young, with a rapidly increasing rate of forming new stars," van Dokkum said. "There are also indications that there is not much neutral hydrogen gas surrounding the galaxy, which would be surprising: the very early universe is expected to be filled with neutral hydrogen. "That needs even better spectra and more galaxies, to investigate more fully."
The presence of carbon and nitrogen in MoM z14 indicates that there are earlier galaxies to be discovered than this 13.52 billion-year-old example.
That is because the very earliest galaxies in the universe and their stars were filled with the simplest elements in the cosmos, hydrogen and helium.
Later galaxies would be populated by these heavier elements, which astronomers somewhat confusingly call "metal," as their stars forged them and then dispersed them in supernova explosions.
"MoM z14 is not one of the very first objects that formed in the universe, as the stars in those galaxies are composed of hydrogen and helium only - we would not see carbon or nitrogen," van Dokkum said. "It could be part of the first wave of formation of 'normal' galaxies, that is, the first galaxies that have elements like nitrogen and carbon - but we've thought that before!"
Related Stories:
— Is our universe trapped inside a black hole? This James Webb Space Telescope discovery might blow your mind
—James Webb Space Telescope finds our Milky Way galaxy's supermassive black hole blowing bubbles (image, video)
— James Webb Space Telescope sees early galaxies defying 'cosmic rulebook' of star formation
As for finding even earlier galaxies than MoM z14 and perhaps even detecting that first generation, van Dokkum is confident that the JWST is up to the task.
He explained: "The JWST continues to push the boundary beyond where we thought it was, and at this point I would not be surprised if we find galaxies at z =15 or z =16!"
For now, van Dokkum and the rest of this team, led by Rohan Naidu of MIT's Kavli Institute for Astrophysics and Space Research, can celebrate breaking new ground in our understanding of the early cosmos."In a program like this, the whole team is always hoping for a 'miracle,' that is, that some of the candidate extremely early galaxies actually pan out and are not 'mirages,' objects whose colors look like extremely early objects," van Dokkum concluded. "While we were hoping for some very early objects, I don't think any of us expected to break the redshift record!"
A pre-peer-reviewed version of the team's research is published on the paper repository site arXiv.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Medscape
8 minutes ago
- Medscape
Which Class of ER Degrader Is Better?
Vepdegestrant, an investigational estrogen receptor (ER) degrader, known as a proteolysis-targeting chimera (PROTAC ), outshone the commonly used selective estrogen receptor degrader (SERD) fulvestrant in a phase 3 trial of second-line treatment for a subset of patients with breast cancer. The VERITAC-2 trial included patients with ER-positive/human epidermal growth factor receptor 2-negative (ER+/HER2-), locally advanced or metastatic disease who had failed prior treatment with cyclin-dependent kinase 4/6 (CDK 4/6) inhibitors and endocrine therapy, and no exposure to chemotherapy in the advanced setting. Only a subset of the study cohort, those with estrogen receptor 1-mutant disease, experienced a statistically significant and clinically meaningful improvement in progression-free survival (PFS) when treated with vepdegestrant compared with patients treated with fulvestrant. 'These results support vepdegestrant as a potential monotherapy treatment option for patients with previously treated ESR1 -mutant ER+/HER2- advanced breast cancer,' said lead author Erika P. Hamilton, MD, a medical oncologist and director of Breast Cancer and Gynecologic Cancer Research at Sarah Cannon Research Institute, Nashville, Tennessee, during a press conference for the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. The findings were simultaneously published in the New England Journal of Medicine . Vepdegestrant is not approved by the US Food and Drug Administration, but received fast-track status in February 2024 as monotherapy for this patient population. It is the first and only PROTAC ER degrader to be evaluated in a phase 3 clinical trial in breast cancer. PROTACs represent a novel class of therapeutic agents that harness the proteasome to selectively degrade target proteins. 'There's no established consensus for patients getting treatment in the second-line setting after progression on endocrine therapy and a CDK 4/6 inhibitor,' explained Hamilton. 'One of the mainstays of our treatment really has been fulvestrant, which clearly has some challenges. First, it's administered intramuscularly, and second, in a post-CDK 4/6 landscape, we know that progression-free survival is very short — on the order of less than 2 months.' Besides fulvestrant, the oral SERD elacestrant was FDA-approved in January 2023, and other oral SERDs are in development, she noted. Trial Design The new trial included 624 patients with advanced ER+/HER2- disease that had progressed following one or two lines of endocrine therapy and a CDK 4/6 inhibitor. 'They could not have received fulvestrant already or chemotherapy, and patients had to have benefited from their previous line of endocrine therapy for at least 6 months to enter the study,' Hamilton noted. Study participants were also stratified by the presence or absence of visceral disease, as well as the presence of an ESR1 mutation (n = 270). Such mutations are a common cause of acquired resistance found in approximately 40% of patients in the second-line setting, according to a press release from the drug developer. Patients were randomly assigned 1:1 to 28-day treatment cycles of either 200 mg oral vepdegestrant once daily, or 500 mg intramuscular fulvestrant on day 1 and day 15 of the first cycle, and then on day 1 of each subsequent cycle. The primary endpoint was PFS by blinded, independent central review, first in patients with ESR1 mutations and then in the entire cohort. Key secondary endpoints were overall survival, objective response rate, and clinical benefit rate, which was defined as the rate of confirmed clinical or partial response at any time, or stable disease, nonclinical response, or nonprogressive disease for at least 24 weeks. Vepdegestrant vs Fulvestrant The study met its key primary endpoint, showing a median PFS of 5.0 months with vepdegestrant compared with 2.1 months with fulvestrant (hazard ratio [HR] 0.57; P < .001) in the 270 patients with ESR1 mutations. At 6 months, twice as many patients in the vepdegestrant arm remained progression-free compared with those in the fulvestrant arm (45.2% vs 22.7%). However, this primary endpoint was not significantly different between groups when calculated for the entire patient population (HR, 0.83; P = .07). For the key secondary endpoints, among patients with ESR1 mutations, the clinical benefit rate was more than double in patients receiving vepdegestrant (42.1% vs 20.2%). Similarly, the objective response rate was more than four times higher (18.6% vs 4%) Commenting in a press release, ASCO breast cancer expert Jane Lowe Meisel, MD, said that although the trial found that vepdegestrant worked better than fulvestrant in patients with ESR1 mutations, 'on average, patients did not have prolonged responses on either agent, highlighting the need for combination therapies and continued development in this space.' Meisel is co-director of Breast Medical Oncology at the Winship Cancer Institute of Emory University School of Medicine in Atlanta, Georgia. 'Overall survival was very immature at the time of this analysis, with only 20% of the anticipated events occurring,' added lead investigator Hamilton. Treatment-emergent adverse events (TEAEs) led to discontinuation in 3% of patients taking vepdegestrant and 1% of patients taking fulvestrant. TEAEs leading to dose reductions occurred in 2% of the vepdegestrant group and none in the fulvestrant group. The three most common AEs of any grade were fatigue (27% in vepdegestrant group, 16% fulvestrant group) and increased aspartate aminotransferase and alanine aminotransferase levels of any grade (14% vepdegestrant group, 10% fulvestrant group). Oral SERDS vs Vepdegestrant Side Effects Compared to oral SERDs, vepdegestrant has a favorable side effect profile, Hamilton said. 'Oral SERDs have prominent GI side effects as their most frequent side effect.' But, across all grades, rates of both vomiting and diarrhea were only 6% with vepdegestrant. GI side effects tend to be more common, 'in the 30% or 40% range with oral SERDs,' she told Medscape Medical News . Study discussant William John Gradishar, MD, emphasized the importance of reducing side effects. ' Vepdegestrant now joins a growing list of drugs that perform better than current standard of care monotherapy' in the ESR1 -mutant population, he noted in the session. But the reality is that most of these drugs are being developed to be used in combination with targeted therapies, 'and increased toxicity can be expected with doublet therapy…Quality of life measures as experienced and reported by patients are critical, and even modest changes in symptom and functional domains should not be minimized,' said Gradishar, professor of breast oncology at Northwestern University Feinberg School of Medicine, Chicago, Illinois. 'Vepdegestrant has demonstrated compelling preclinical activity and encouraging early clinical data supporting its efficacy in degrading ER,' said Albert Grinshpun, MD, in an interview with Medscape Medical News . Grinshpun, head of the Breast Cancer Service at Shaare Zedek Medical Center and The Hebrew University, Jerusalem, Israel, said his initial takeaway from the study is that 'vepdegestrant now stands alongside other oral SERDs, such as elacestrant and imlunestrant, in demonstrating superiority over fulvestrant, specifically in the context of ESR1 -mutant [disease].' 'Importantly, the treatment landscape for patients progressing on CDK 4/6 inhibitors is rapidly evolving, with a growing shift toward combination therapies rather than fulvestrant monotherapy,' he said. 'In my view, vepdegestrant has established itself as a promising endocrine backbone for future combination strategies. Its favorable toxicity profile makes it particularly well-suited for pairing with a range of targeted agents or even antibody-drug conjugates, including inhibitors of PIK3CA and KAT6 , in the pursuit of more effective therapeutic regimens.' The study was jointly funded by Arvinas Estrogen Receptor, Inc. and Pfizer. Hamilton disclosed consulting or advisory roles with Accutar Biotechnology (Inst), Arvinas (Inst), AstraZeneca (Inst), Circle Pharma (Inst), Daiichi Sankyo (Inst), Ellipses Pharma (Inst), Entos (Inst), Fosun Pharma (Inst), Genentech/Roche (Inst), Gilead Sciences (Inst), Janssen (Inst), Jazz Pharmaceuticals (Inst), Jefferies (Inst), Johnson & Johnson (Inst), Lilly (Inst), Medical Pharma Services (Inst), Mersana (Inst), Novartis (Inst), Olema Pharmaceuticals (Inst), Pfizer (Inst), Stemline Therapeutics (Inst), Tempus (Inst), Theratechnologies (Inst), Tubulis GmbH (Inst), Verascity Science (Inst), and Zentalis (Inst). Hamilton has also received research funding from AbbVie (Inst), Accutar Biotech (Inst), Acerta Pharma (Inst), ADC Therapeutics (Inst), Akeso Biopharma (Inst), Amgen (Inst), Aravive (Inst), ArQule (Inst), Artios (Inst), Arvinas (Inst), AstraZeneca (Inst), AtlasMedx (Inst), BeiGene (Inst), Black Diamond Therapeutics (Inst), Bliss Biopharmaceutical (Inst), Boehringer Ingelheim (Inst), Bristol-Myers Squibb (Inst), Cascadian Therapeutics (Inst), Clovis Oncology (Inst), Compugen (Inst), Context Therapeutics (Inst), Cullinan Oncology (Inst), Curis (Inst), CytomX Therapeutics (Inst), Daiichi Sankyo (Inst), Dana-Farber Cancer Institute (Inst), Dantari (Inst), Deciphera (Inst), Duality Biologics (Inst), eFFECTOR Therapeutics (Inst), Eisai (Inst), Ellipses Pharma (Inst), Elucida Oncology (Inst), EMD Serono (Inst), Fochon Pharmaceuticals (Inst), Fujifilm (Inst), G1 Therapeutics (Inst), Genentech/Roche (Inst), Gilead Sciences (Inst), H3 Biomedicine (Inst), Harpoon (Inst), Hutchison MediPharma (Inst), Immunogen (Inst), Immunomedics (Inst), Incyte (Inst), Infinity Pharmaceuticals (Inst), Inspirna (Inst), InventisBio (Inst), Jacobio (Inst), K-Group Beta (Inst), Karyopharm Therapeutics (Inst), Kind Pharmaceuticals (Inst), Leap Therapeutics (Inst), Lilly (Inst), Loxo (Inst), Lycera (Inst), MabSpace Biosciences (Inst), Macrogenics (Inst), MedImmune (Inst), Mersana (Inst), Merus (Inst), Millennium (Inst), Molecular Templates (Inst), Myriad Genetics (Inst), Novartis (Inst), Nucana (Inst), Olema Pharmaceuticals (Inst), OncoMed (Inst), Oncothyreon (Inst), ORIC Pharmaceuticals (Inst), Orinove (Inst), Orum Therapeutics (Inst), Pfizer (Inst), PharmaMar (Inst), Pieris Pharmaceuticals (Inst), Pionyr (Inst), Plexxikon (Inst), Prelude Therapeutics (Inst), ProfoundBio (Inst), Radius Health (Inst), Regeneron (Inst), Relay Therapeutics (Inst), Repertoire Immune Medicines (Inst), Rgenix (Inst), Seagen (Inst), Sermonix Pharmaceuticals (Inst), Shattuck Labs (Inst), Silverback Therapeutics (Inst), Stem CentRx (Inst), Stemline Therapeutics (Inst), Sutro Biopharma (Inst), Syndax (Inst), Syros Pharmaceuticals (Inst), Taiho Pharmaceutical (Inst), TapImmune Inc. (Inst), Tesaro (Inst), Tolmar (Inst), Torque (Inst), Treadwell Therapeutics (Inst), Verastem (Inst), Zenith Epigenetics (Inst), and Zymeworks (Inst). Meisel disclosed consulting or advisory roles with AstraZeneca, GE Healthcare, Genentech, Novartis, Olema Oncology, Pfizer, SeaGen, Sermonix Pharmaceuticals, and Stemline, and research funding from AstraZeneca (Inst), Olema Oncology (Inst), Pfizer (Inst), Seagen (Inst), and Sermonix Pharmaceuticals (Inst). Grinshpun disclosed honoraria from GSK, Lilly, Novartis, and AstraZeneca, and travel from Roche, Pfizer, and AstraZeneca. Gradishar disclosed consulting or advisory roles with AstraZeneca , Genentech/Roche, Gilead Sciences, Merck, Novartis, Pfizer.


CBS News
13 minutes ago
- CBS News
Transcript: Rep. Raja Krishnamoorthi on "Face the Nation with Margaret Brennan," June 1, 2025
The following is the transcript of an interview with Rep. Raja Krishnamoorthi, Democrat of Illinois, that aired on "Face the Nation with Margaret Brennan" on June 1, 2025. MARGARET BRENNAN: We turn now to the top Democrat on the House Select Committee on the Chinese Communist Party, that's Congressman Raja Krishnamoorthi. He's in Illinois. Good morning to you. I want to get-- REP. KRISHNAMOORTHI: --Good morning. MARGARET BRENNAN: I want to get straight to it. You heard from the Secretary of State this week that the State Department is going to work with Homeland Security to aggressively revoke visas for Chinese students, including those with connections to the Chinese Communist Party or studying in critical fields. There are like 300,000 Chinese students with visas in this country. The U.S. government already has a heightened level of vetting. What's going to change? REP. KRISHNAMOORTHI: I don't know. There's not enough details, but what it looks like if they're targeting all people of Chinese origin who are on international student visas because he's not limiting it to just people who might have ties to the Chinese Communist Party, and if they do have those ties, they don't belong here, especially if they're committing nefarious acts. However, this appears to be much broader and it's terribly misguided and it appears prejudicial and discriminatory. My own father was, came here on an international student visa. And I believe that these people are vital for our economy and for entrepreneurship in this country. And I think this is going to harm America more than help. MARGARET BRENNAN: You said if someone has ties to the Chinese Communist Party they shouldn't be here. Does that mean all the, the students who are children of leaders, for example Xi Jinping's own daughter, shouldn't have been allowed here? REP. KRISHNAMOORTHI: Well, if they were engaged in nefarious activities and if they are somehow deeply connected to the CCP, I think that we should be very careful. But in this particular case, they're not only going after people who might fall in that category, but it's anybody who is from China, including Hong Kong by the way, where people are actually persecuted for various freedoms they're trying to exercise, and who come here seeking to exercise those freedoms. So this is a terrible, terribly misguided policy. MARGARET BRENNAN: The Biden administration did conduct heightened vetting, as you know, of Chinese students. Do you think that there is a legitimate argument for expanding this, that certain areas should just be off limits? REP. KRISHNAMOORTHI: I think that you should definitely have heightened vetting, especially in certain critical areas because we know that the CCP tries to steal, for instance, intellectual property or worse. But the way that this is currently structured looks very, very suspicious and you have to remember that the people that are cheering for this policy, what Marco Rubio had called for, is the Chinese Communist Party. Why? Because they want these people back. They want the scientists and the entrepreneurs and the engineers who can come and help their economy. And so we are probably helping them, as well as other countries, more than helping ourselves with this policy. MARGARET BRENNAN: The Defense Secretary is traveling in Asia right now and he said in a defense forum speech that Beijing is quote "concretely and credibly preparing to use military force." He said their military is rehearsing. Take a listen. PETE HEGSETH: Any attempt by Communist China to conquer Taiwan by force would result in devastating consequences for the Indo-Pacific and the world. There's no reason to sugar coat it. The threat China poses is real and it could be imminent. MARGARET BRENNAN: He did not say what the consequences would be. Are you encouraged by what appears to be a statement of support for allies? REP. KRISHNAMOORTHI: I am. I think what he's saying is largely correct, but I think the problem is at the same time he says that, either Donald Trump or even him or others say other things that push away our friends, partners and allies in the region and cause confusion. And so we need to be consistent and thoughtful with regard to our statements, and we need to be also very methodical about our actions in trying to curb military aggression by the Chinese Communist Party in the South China Sea and with regard to Taiwan. MARGARET BRENNAN: Since you track U.S. intelligence, I wanted to ask you if you have any insight into what appears to be the swarm of Ukrainian drones that has destroyed 40 Russian military aircraft deep inside Russian territory overnight. Sources are telling our Jennifer Jacobs that the White House wasn't aware that this attack was planned. What can you tell us about the level of US intelligence sharing with Ukraine right now and helping them with their targets? REP. KRISHNAMOORTHI: I don't want to get into classified information, but what I can say is that it's a little bit more strained in light of what Donald Trump has said recently. The one thing that I can also say is that Trump was right the other day to say that Putin is crazy in the way that he's going after civilian areas in Ukraine repeatedly, and so the Ukrainians are striking back. At the end of the day, the only way that we can bring these hostilities to an end is by strengthening the hand of the Ukrainians. Trump should, at this point, realize that Putin is playing him and aid the Ukrainians in their battlefield efforts. That's the best way to get to some type of armistice or truce at the negotiating table sooner rather than later. MARGARET BRENNAN: All right, Congressman Krishnamoorthi thank you for your insights today.


News24
18 minutes ago
- News24
‘Love you guys,' says coach Salam as he parts ways with Marumo Gallants after clean rescue
Be among those who shape the future with knowledge. Uncover exclusive stories that captivate your mind and heart with our FREE 14-day subscription trial. Dive into a world of inspiration, learning, and empowerment. You can only trial once.